The effect of inhibition of receptor tyrosine kinase AXL on DNA damage response in ovarian cancer

AXL is a receptor tyrosine kinase that is often overexpressed in cancers. It contributes to pathophysiology in cancer progression and therapeutic resistance, making it an emerging therapeutic target. The first-in-class AXL inhibitor bemcentinib (R428/BGB324) has been granted fast track designation b...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeo, Xun Hui, Sundararajan, Vignesh, Wu, Zhengwei, Phua, Zi Jin Cheryl, Ho, Yin Ying, Peh, Kai Lay Esther, Chiu, Yi-Chia, Tan, Tuan Zea, Kappei, Dennis, Ho, Ying Swan, Tan, David Shao Peng, Tam, Wai Leong, Huang, Ruby Yun-Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10287694/
https://www.ncbi.nlm.nih.gov/pubmed/37349576
http://dx.doi.org/10.1038/s42003-023-05045-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10287694/
https://www.ncbi.nlm.nih.gov/pubmed/37349576
http://dx.doi.org/10.1038/s42003-023-05045-0

Ejemplares similares